The role of the microbiota in neurological diseases

Fernando Leal-Martínez , Irene Alejandra Berumen Coronado

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004150

PDF (2215KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004150 DOI: 10.37349/ent.2026.1004150
Review
research-article
The role of the microbiota in neurological diseases
Author information +
History +
PDF (2215KB)

Abstract

Growing evidence has directly linked the gastrointestinal tract, gut microbiota, and central nervous system, forming the gut-brain axis, a process that has been described as a key mechanism in regulating neurological processes. However, the presence of alterations in the composition of microorganisms in the digestive tract and dysbiosis has been linked to the activation of microglia, increased oxidative stress, alterations in the production of neurotransmitters, and exacerbation of neuroinflammation. These mechanisms have been associated with multiple pathologies and neurological conditions, and regulating them is key to the control of these diseases. In this context, various bacterial species play a neuroprotective role by promoting the integrity of the intestinal barrier, stimulating the synthesis of beneficial metabolites such as short-chain fatty acids (SCFAs), neurotransmitters, and modulating the inflammatory response. In addition, the characterization of these microbial profiles provides a broad perspective on understanding how changes in the microbiota contribute to the progression of neurological diseases. On the other hand, these new updates open up the possibility of designing personalised targeted therapeutic interventions that can regulate the gut microbiota and promote a neuroprotective and neuroregenerative environment. Another key point is that greater emphasis is placed on the need for more controlled clinical studies to validate efficacy and safety in humans, as well as knowledge of the mechanisms of action that make them possible. Finally, the modulation of the gut microbiota using probiotics, prebiotics, and postbiotics represents an innovative and effective opportunity to intervene in neuroimmune processes such as microglial activation, regulation of synaptic pruning, and neuroinflammatory pathways-processes implicated in various neurological diseases. In this context, this review integrates and analyzes the available evidence, highlighting potential interventions as treatments for these pathologies, as well as current limitations, to provide an updated framework to guide future research.

Keywords

gut microbiota / neuroinflammation / microglial activation / neurodegenerative diseases / gut-brain axis

Cite this article

Download citation ▾
Fernando Leal-Martínez, Irene Alejandra Berumen Coronado. The role of the microbiota in neurological diseases. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004150 DOI:10.37349/ent.2026.1004150

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Harris E. Neurological Conditions Are Leading Cause of Disability Worldwide. JAMA. 2024; 331: 1440.

[2]

GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024; 23: 344-81.

[3]

Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020; 19: 255-65.

[4]

Winkler AS. The growing burden of neurological disorders in low-income and middle-income countries: priorities for policy making. Lancet Neurol. 2020; 19: 200-2.

[5]

Bassetti CLA, Accorroni A, Arnesen A, Basri HB, Berger T, Berlit P, et al. General neurology: Current challenges and future implications. Eur J Neurol. 2024; 31: e16237.

[6]

Zhang R, Ding N, Feng X, Liao W. The gut microbiome, immune modulation, and cognitive decline: insights on the gut-brain axis. Front Immunol. 2025; 16: 1529958.

[7]

Bairamian D, Sha S, Rolhion N, Sokol H, Dorothée G, Lemere CA, et al. Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease. Mol Neurodegener. 2022; 17: 19.

[8]

Intili G, Paladino L, Rappa F, Alberti G, Plicato A, Calabrò F, et al. From Dysbiosis to Neurodegenerative Diseases through Different Communication Pathways: An Overview. Biology (Basel). 2023; 12: 195.

[9]

Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH, Yeow SH, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther. 2024; 9: 37.

[10]

Hu X, Jin H, Yuan S, Ye T, Chen Z, Kong Y, et al. Fecal microbiota transplantation inhibited neuroinflammation of traumatic brain injury in mice via regulating the gut-brain axis. Front Cell Infect Microbiol. 2023; 13: 1254610.

[11]

Rosales Contreras NM, Sierra Ramírez JA, Monserrath Loza M, de la O Gómez AT. The Inner Ecosystem of the Human Body: How the Gut Microbiota Protects Your Health. Revista Científica y Académica. 2025; 5: 634-53. Spanish.

[12]

Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, et al. Human gut microbiota in health and disease: Unveiling the relationship. Front Microbiol. 2022; 13: 999001.

[13]

Yang K, Li G, Li Q, Wang W, Zhao X, Shao N, et al. Distribution of gut microbiota across intestinal segments and their impact on human physiological and pathological processes. Cell Biosci. 2025; 15: 47.

[14]

Núñez I, Uzcátegui Montero OE, Sandó Mistage C, Terrizzi A, Milano A, Martínez B. Current Aspects of the Microbiota and its Relationship with Pregnancy. Rev Obstet Ginecol Venez. 2024; 84: 450-8. Spanish.

[15]

Panzer JJ, Romero R, Greenberg JM, Winters AD, Galaz J, Gomez-Lopez N, et al. Is there a placental microbiota? A critical review and re-analysis of published placental microbiota datasets. BMC Microbiol. 2023; 23: 76.

[16]

Uberos J. Perinatal microbiota: review of its importance in newborn health. Arch Argent Pediatr. 2020; 118: e265-70.

[17]

Miller C, Luu K, Mikami B, Riel J, Qin Y, Khadka V, et al. Temporal Investigation of the Maternal Origins of Fetal Gut Microbiota. Microorganisms. 2024; 12: 1865.

[18]

Parker A, Romano S, Ansorge R, Aboelnour A, Le Gall G, Savva GM, et al. Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain. Microbiome. 2022; 10: 68.

[19]

Xie J, Kim T, Liu Z, Panier H, Bokoliya S, Xu M, et al. Young gut microbiota transplantation improves the metabolic health of old mice. mSystems. 2025; 10: e01601-24.

[20]

Álvarez J, Fernández Real JM, Guarner F, Gueimonde M, Rodríguez JM, Saenz de Pipaon M, et al. Gut microbes and health. Gastroenterol Hepatol. 2021; 44: 519-35.

[21]

Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2024; 19: 275-93.

[22]

Kostiuchenko O, Lushnikova I, Skibo G. The role of gut microbiota metabolites in the regeneration and protection of nervous tissue: a narrative review. Regener Med Rep. 2024; 1: 12-30.

[23]

Kuang J, Zheng X, Jia W. Investigating regional-specific gut microbial distribution: an uncharted territory in disease therapeutics. Protein Cell. 2025; 16: 623-40.

[24]

Naufel MF, Truzzi GM, Ferreira CM, Coelho FMS. The brain-gut-microbiota axis in the treatment of neurologic and psychiatric disorders. Arq Neuropsiquiatr. 2023; 81: 670-84.

[25]

Yang H, Liu Y, Cai R, Li Y, Gu B. A narrative review of relationship between gut microbiota and neuropsychiatric disorders: mechanisms and clinical application of probiotics and prebiotics. Ann Palliat Med. 2021; 10: 2304-13.

[26]

Gomez-Eguilaz M, Ramon-Trapero JL, Perez-Martinez L, Blanco JR. The microbiota-gut-brain axis and its great projections. Rev Neurol. 2019; 68: 111-7. Spanish.

[27]

Bonaz B, Bazin T, Pellissier S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front Neurosci. 2018; 12: 49.

[28]

Choi W, Moon JH, Kim H. Serotonergic regulation of energy metabolism in peripheral tissues. J Endocrinol. 2020; 245: R1-10.

[29]

Kanova M, Kohout P. Serotonin-Its Synthesis and Roles in the Healthy and the Critically Ill. Int J Mol Sci. 2021; 22: 4837.

[30]

Shaw C, Hess M, Weimer BC. Microbial-Derived Tryptophan Metabolites and Their Role in Neurological Disease: Anthranilic Acid and Anthranilic Acid Derivatives. Microorganisms. 2023; 11: 1825.

[31]

Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015; 161: 264-76.

[32]

Bonmatí-Carrión MÁ, Rol MA. Melatonin as a Mediator of the Gut Microbiota-Host Interaction: Implications for Health and Disease. Antioxidants (Basel). 2024; 13: 34.

[33]

Braga JD, Thongngam M, Kumrungsee T. Gamma-aminobutyric acid as a potential postbiotic mediator in the gut-brain axis. NPJ Sci Food. 2024; 8: 16.

[34]

Jang SH, Woo YS, Lee SY, Bahk WM. The Brain-Gut-Microbiome Axis in Psychiatry. Int J Mol Sci. 2020; 21: 7122.

[35]

Hamamah S, Aghazarian A, Nazaryan A, Hajnal A, Covasa M. Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling. Biomedicines. 2022; 10: 436.

[36]

Pang S, Ren Z, Ding H, Chan P. Short-chain fatty acids mediate enteric and central nervous system homeostasis in Parkinson’s disease: Innovative therapies and their translation. Neural Regen Res. 2026; 21: 938-56.

[37]

Chakrabarti A, Geurts L, Hoyles L, Iozzo P, Kraneveld AD, La Fata G, et al. The microbiota-gut-brain axis: pathways to better brain health. Perspectives on what we know, what we need to investigate and how to put knowledge into practice. Cell Mol Life Sci. 2022; 79: 80.

[38]

Zhang LY, Zhang SY, Wen R, Zhang TN, Yang N. Role of histone deacetylases and their inhibitors in neurological diseases. Pharmacol Res. 2024; 208: 107410.

[39]

Yang LL, Millischer V, Rodin S, MacFabe DF, Villaescusa JC, Lavebratt C. Enteric short-chain fatty acids promote proliferation of human neural progenitor cells. J Neurochem. 2020; 154: 635-46.

[40]

Cao Q, Shen M, Li R, Liu Y, Zeng Z, Zhou J, et al. Elucidating the specific mechanisms of the gut-brain axis: the short-chain fatty acids-microglia pathway. J Neuroinflammation. 2025; 22: 133.

[41]

Rusch JA, Layden BT, Dugas LR. Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis. Front Endocrinol (Lausanne). 2023; 14: 1130689.

[42]

Tofani GSS, Leigh SJ, Gheorghe CE, Bastiaanssen TFS, Wilmes L, Sen P, et al. Gut microbiota regulates stress responsivity via the circadian system. Cell Metab. 2025; 37: 138-53.e5.

[43]

Bertollo AG, Santos CF, Bagatini MD, Ignácio ZM. Hypothalamus-pituitary-adrenal and gut-brain axes in biological interaction pathway of the depression. Front Neurosci. 2025; 19: 1541075.

[44]

Warren A, Nyavor Y, Zarabian N, Mahoney A, Frame LA. The microbiota-gut-brain-immune interface in the pathogenesis of neuroinflammatory diseases: a narrative review of the emerging literature. Front Immunol. 2024; 15: 1365673.

[45]

Yuan C, He Y, Xie K, Feng L, Gao S, Cai L. Review of microbiota gut brain axis and innate immunity in inflammatory and infective diseases. Front Cell Infect Microbiol. 2023; 13: 1282431.

[46]

Oyovwi MO, Uchechukwu GJ, Oyekanmi BA, Odokuma EI, Ogenma UT. Gut Microbiota and Neuroinflammation: An Interconnected Nexus of Health and Neurodegenerative Disease. OBM Neurobiol. 2024; 8: 254.

[47]

Chen L, Zhang L, Hua H, Liu L, Mao Y, Wang R. Interactions between toll-like receptors signaling pathway and gut microbiota in host homeostasis. Immun Inflamm Dis. 2024; 12: e1356.

[48]

Pacheco R. Cross-talk between T-cells and gut-microbiota in neurodegenerative disorders. Neural Regen Res. 2019; 14: 2091-2.

[49]

Erny D, Dokalis N, Mezö C, Castoldi A, Mossad O, Staszewski O, et al. Microbiota-derived acetate enables the metabolic fitness of the brain innate immune system during health and disease. Cell Metab. 2021; 33: 2260-76.e7.

[50]

Mossad O, Batut B, Yilmaz B, Dokalis N, Mezö C, Nent E, et al. Gut microbiota drives age-related oxidative stress and mitochondrial damage in microglia via the metabolite N6-carboxymethyllysine. Nat Neurosci. 2022; 25: 295-305.

[51]

Ma M, Jiang W, Zhou R. DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity. 2024; 57: 752-71.

[52]

Buga AM, Padureanu V, Riza AL, Oancea CN, Albu CV, Nica AD. The Gut-Brain Axis as a Therapeutic Target in Multiple Sclerosis. Cells. 2023; 12: 1872.

[53]

D’Alessandro G, Marrocco F, Limatola C. Microglial cells: Sensors for neuronal activity and microbiota-derived molecules. Front Immunol. 2022; 13: 1011129.

[54]

Ortiz-Samur NS, Vijaya AK, Burokas A, Mela V. Exploring the Role of Microglial Cells in the Gut-Brain Axis Communication: A Systematic Review. J Neurochem. 2025; 169: e70154.

[55]

O’Riordan KJ, Moloney GM, Keane L, Clarke G, Cryan JF. The gut microbiota-immune-brain axis: Therapeutic implications. Cell Rep Med. 2025; 6: 101982.

[56]

Li T, Chu C, Yu L, Zhai Q, Wang S, Zhao J, et al. Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease. Nutrients. 2022; 14: 4678.

[57]

Asaoka D, Xiao J, Takeda T, Yanagisawa N, Yamazaki T, Matsubara Y, et al. Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial. J Alzheimers Dis. 2022; 88: 75-95.

[58]

Kobayashi Y, Kinoshita T, Matsumoto A, Yoshino K, Saito I, Xiao JZ. Bifidobacterium Breve A1 Supplementation Improved Cognitive Decline in Older Adults with Mild Cognitive Impairment: An Open-Label, Single-Arm Study. J Prev Alzheimers Dis. 2019; 6: 70-5.

[59]

Xiao J, Katsumata N, Bernier F, Ohno K, Yamauchi Y, Odamaki T, et al. Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial. J Alzheimers Dis. 2020; 77: 139-47.

[60]

Li X, Zheng P, Cao W, Cao Y, She X, Yang H, et al. Lactobacillus rhamnosus GG ameliorates noise-induced cognitive deficits and systemic inflammation in rats by modulating the gut-brain axis. Front Cell Infect Microbiol. 2023; 13: 1067367.

[61]

Aktas B, Aslim B, Ozdemir DA. A neurotherapeutic approach with Lacticaseibacillus rhamnosus E9 on gut microbiota and intestinal barrier in MPTP-induced mouse model of Parkinson’s disease. Sci Rep. 2024; 14: 15460.

[62]

Wang L, Zhao R, Li X, Shao P, Xie J, Su X, et al. Lactobacillus rhamnosus GG improves cognitive impairments in mice with sepsis. PeerJ. 2024; 12: e17427.

[63]

Sanborn V, Azcarate-Peril MA, Updegraff J, Manderino L, Gunstad J. Randomized Clinical Trial Examining the Impact of Lactobacillus rhamnosus GG Probiotic Supplementation on Cognitive Functioning in Middle-aged and Older Adults. Neuropsychiatr Dis Treat. 2020; 16: 2765-77.

[64]

Ruiz-Gonzalez C, Cardona D, Rueda-Ruzafa L, Rodriguez-Arrastia M, Ropero-Padilla C, Roman P. Cognitive and Emotional Effect of a Multi-species Probiotic Containing Lactobacillus rhamnosus and Bifidobacterium lactis in Healthy Older Adults: A Double-Blind Randomized Placebo-Controlled Crossover Trial. Probiotics Antimicrob Proteins. 2025; 17: 3525-37.

[65]

Di Salvo C, D’Antongiovanni V, Benvenuti L, d’Amati A, Ippolito C, Segnani C, et al. Lactiplantibacillus plantarum HEAL9 attenuates cognitive impairment and progression of Alzheimer’s disease and related bowel symptoms in SAMP8 mice by modulating microbiota-gut-inflammasome-brain axis. Food Funct. 2024; 15: 10323-38.

[66]

Lu CS, Chang HC, Weng YH, Chen CC, Kuo YS, Tsai YC. The Add-On Effect of Lactobacillus plantarum PS128 in Patients With Parkinson’s Disease: A Pilot Study. Front Nutr. 2021; 8: 650053.

[67]

Liao JF, Cheng YF, You ST, Kuo WC, Huang CW, Chiou JJ, et al. Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson’s disease. Brain Behav Immun. 2020; 90: 26-46.

[68]

Wong LC, Hsu CJ, Wu YT, Chu HF, Lin JH, Wang HP, et al. Investigating the impact of probiotic on neurological outcomes in Rett syndrome: A randomized, double-blind, and placebo-controlled pilot study. Autism. 2024; 28: 2267-81.

[69]

Tao D, Zhong T, Pang W, Li X. Saccharomyces boulardii improves the behaviour and emotions of spastic cerebral palsy rats through the gut-brain axis pathway. BMC Neurosci. 2021; 22: 76.

[70]

Ipek ED, Basaloglu H. Neuroprotective effects of Saccharomyces boulardii and bacterial probiotics in a rotenone-induced rat model of Parkinson’s disease. Folia Morphol (Warsz). 2026; 85: e01726014.

[71]

Roy Sarkar S, Mitra Mazumder P, Chatterjee K, Sarkar A, Adhikary M, Mukhopadhyay K, et al. Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline. Physiol Behav. 2021; 236: 113411.

[72]

Kang EJ, Cha MG, Kwon GH, Han SH, Yoon SJ, Lee SK, et al. Akkermansia muciniphila improve cognitive dysfunction by regulating BDNF and serotonin pathway in gut-liver-brain axis. Microbiome. 2024; 12: 181.

[73]

Ou Z, Deng L, Lu Z, Wu F, Liu W, Huang D, et al. Protective effects of Akkermansia muciniphila on cognitive deficits and amyloid pathology in a mouse model of Alzheimer’s disease. Nutr Diabetes. 2020; 10: 12.

[74]

Kunevičius A, Vijaya AK, Atzeni A, Mingaila J, Šimoliūnė I, Jamontas R, et al. Intermittent supplementation with Akkermansia muciniphila and galactooligosaccharides modulates Alzheimer’s disease progression, gut microbiota, and colon short-chain fatty acid profiles in mice. Front Aging Neurosci. 2025; 17: 1617980.

[75]

Ma YY, Li X, Yu JT, Wang YJ. Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside. Transl Neurodegener. 2024; 13: 12.

[76]

Qu L, Li Y, Liu F, Fang Y, He J, Ma J, et al. Microbiota-Gut-Brain Axis Dysregulation in Alzheimer’s Disease: Multi-Pathway Effects and Therapeutic Potential. Aging Dis. 2024; 15: 1108-31.

[77]

Zhang X, Tang B, Guo J. Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies. Transl Neurodegener. 2023; 12: 59.

[78]

Poluektova EU, Stavrovskaya A, Pavlova A, Yunes R, Marsova M, Koshenko T, et al. Gut Microbiome as a Source of Probiotic Drugs for Parkinson’s Disease. Int J Mol Sci. 2025; 26: 9290.

[79]

Ayala V, Fontdevila L, Rico-Rios S, Povedano M, Andrés-Benito P, Torres P, et al. Microbial Influences on Amyotrophic Lateral Sclerosis: The Gut-Brain Axis and Therapeutic Potential of Microbiota Modulation. Sclerosis. 2025; 3: 8.

[80]

Limas Solano LM, Vargas Niño CE, Valbuena Rodríguez DC, Ramírez López LX. Fecal Microbial Transplantation: A Review. Rev Colomb Gastroenterol. 2020; 35: 329-37.

[81]

Caetano-Silva ME, Rund L, Hutchinson NT, Woods JA, Steelman AJ, Johnson RW. Inhibition of inflammatory microglia by dietary fiber and short-chain fatty acids. Sci Rep. 2023; 13: 2819.

[82]

Wynn AB, Beyer G, Richards M, Ennis LA. Procedure, Screening, and Cost of Fecal Microbiota Transplantation. Cureus. 2023; 15: e35116.

[83]

Keller JJ, Ooijevaar RE, Hvas CL, Terveer EM, Lieberknecht SC, Högenauer C, et al. A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. United European Gastroenterol J. 2021; 9: 229-47.

[84]

Lee JY, Kim Y, Kim J, Kim JK. Fecal Microbiota Transplantation: Indications, Methods, and Challenges. J Microbiol. 2024; 62: 1057-74.

[85]

Suganya K, Koo BS. Gut-Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions. Int J Mol Sci. 2020; 21: 7551.

[86]

Bi M, Liu C, Wang Y, Liu SJ. Therapeutic Prospect of New Probiotics in Neurodegenerative Diseases. Microorganisms. 2023; 11: 1527.

[87]

Fekete M, Lehoczki A, Major D, Fazekas-Pongor V, Csípő T, Tarantini S, et al. Exploring the Influence of Gut-Brain Axis Modulation on Cognitive Health: A Comprehensive Review of Prebiotics, Probiotics, and Symbiotics. Nutrients. 2024; 16: 789.

[88]

Patricio-Martínez A, Patricio F, Macuil-Chapuli E, Martínez-Juárez EÁ, Flores-Díaz S, Cedillo-Ramírez ML, et al. The role of probiotics, prebiotics, and postbiotics: cellular and molecular pathways activated on glial cells in Alzheimer’s disease. Front Neurosci. 2025; 19: 1598011.

PDF (2215KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉